SCHEMBL6672060

SCHEMBL6672060

COc1cc(Br)cc2c1CN(C(c1ccccc1)(c1ccccc1)c1ccccc1)C2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.35
NQO2 P16083 1/20 0.35
LMNA P02545 3/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 2/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
THRB P10828 1/20 0.33
ALOX12 P18054 1/20 0.33
NQO1 P15559 1/20 0.33
MAOB P27338 1/20 0.32
NPY2R P49146 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670190 0.82 DYRK1A (0.34) LMNAMAPTALDH1A1HPGDKDM4E
SCHEMBL16249200 0.79 KMT2A (0.45) MAPTKDM4EGAAMEN1CYP1A2
SCHEMBL6668669 0.79 KCNH2 (0.31) SIGMAR1
SCHEMBL383295 0.73 HSD17B3 (0.40) ALDH1A1
Anisole SCHEMBL28126761 0.72 CA4 (0.47) NQO2LMNAMAPTALDH1A1HPGD
SCHEMBL13027976 0.69 CHRNA7 (0.43) GAAMEN1CYP1A2CYP3A4CYP2C9
SCHEMBL25223676 0.69 ASIC3 (0.44) FAAH
SCHEMBL14101064 0.69 HSD17B3 (0.42) FAAHMAPT
SCHEMBL30816712 0.68 GAA (0.47) KDM4EGAATSHRDRD4SIGMAR1
SCHEMBL3873268 0.68 ABHD6 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1227096-B1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE SATO PHARMA (JP) 2004-09-22 EP disclosed
US-6525066-B2 Bactericides; side effect reduction SATO PHARMACEUTICAL CO., LTD. (JP) 2003-02-25 US disclosed
US-20020173517-A1 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2002-11-21 US disclosed
EP-1227096-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2002-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173517-A1 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure IL4I1, TLR5, IFNG FAAH 3980/4885NQO2 45/4885LMNA 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.